A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults

Novavax

Status and phase: Completed; Phase 2

Conditions: Influenza

Treatments: Biological: Novavax Trivalent vaccine; Biological: cTIV; Biological: Novavax Quadrivalent vaccine

Study type: Interventional

Funder types: Industry; Other U.S. Federal agency

Identifiers

NCT01561768

NVX 778.S205

Details and patient eligibility

About

The purpose of this study is to determine the immune response of three dose levels of the Novavax Quadrivalent vaccine in healthy young adults (18-64). The study is broken down into 5 treatment groups. Each group will enroll 100 subjects, for a total of 500 subjects. Group 1-3 will receive one of three dose levels of the Novavax Quadrivalent vaccine, Group 4 will receive a dose of the Novavax Trivalent vaccine, and Group 5 will receive a commercially available trivalent influenza vaccine (TIV). The study will also evaluate the safety and tolerability of the Novavax Quadrivalent vaccine.

Enrollment: 500 patients

Sex: All

Ages: 18 to 64 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy adult male or females, 18-64 years of age
2. Willing and able to give informed consent prior to study enrollment
3. Able to comply with study requirements
4. Women who are not post-menopausal (≥ 50 years of age and at least one year post last menses) or surgically sterile must have a negative urine pregnancy test at vaccination; will be advised through the Informed Consent process to avoid becoming pregnant over the duration of the study, and must assert that they will employ an effective form of birth control for the duration of the study. Acceptable forms of birth control are: credible history of abstinence from heterosexual activity, hormonal contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives (condom or diaphragm, with spermicide), and intrauterine device (IUD)

Exclusion criteria

1. Participation in research involving investigational product (drug/biologic/device) within 45 days before planned date of first vaccination
2. History of a serious reaction to prior influenza vaccination, known allergy to constituents of licensed TIV (e.g., egg proteins) or polysorbate-80
3. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza vaccine
4. Received any vaccine in the 4 weeks preceding the study vaccination and any influenza vaccine within six months preceding the study vaccination
5. Any know or suspected immunosuppressive illness, congenital or acquired, based on medical history and/or physical examination
6. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
7. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study
8. Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature >38.0°C on the planned day of vaccine administration)
9. Presence of chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, neurologic, hematologic or metabolic (including diabetes mellitus) disorders, which would include the potential subject in a "high-risk" category for influenza and/or its complications
10. Known disturbance of coagulation
11. Women who are breastfeeding or plan to become pregnant during the study
12. Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse
13. Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting)

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

500 participants in 5 patient groups

Group 1

Experimental group

Treatment:

Biological: Novavax Quadrivalent vaccine

Biological: Novavax Quadrivalent vaccine

Biological: Novavax Quadrivalent vaccine

Group 2

Experimental group

Treatment:

Biological: Novavax Quadrivalent vaccine

Biological: Novavax Quadrivalent vaccine

Biological: Novavax Quadrivalent vaccine

Group 3

Experimental group

Treatment:

Biological: Novavax Quadrivalent vaccine

Biological: Novavax Quadrivalent vaccine

Biological: Novavax Quadrivalent vaccine

Group 4

Experimental group

Treatment:

Biological: Novavax Trivalent vaccine

Group 5

Experimental group

Treatment:

Biological: cTIV